Beyond Anatomy: Molecular Imaging in NHP Models For Translational Drug Development - News

Beyond Anatomy: Molecular Imaging in NHP Models

📅 September 10, 2026 EDT 21:00 / PDT 18:00

Register Now

Molecular imaging is increasingly being used to generate quantitative and longitudinal evidence throughout preclinical drug development. When combined with well-characterized non-human primate (NHP) models , imaging can help researchers move beyond conventional endpoint measurements to investigate where a therapeutic goes, whether it reaches and engages its intended target, and how biological responses evolve over time.

The webinar will focus on the practical value of integrating molecular imaging with NHP disease models, PK/PD, biomarkers and other pharmacological endpoints to generate a more comprehensive translational dataset.

Molecular Imaging in NHP Models

In this webinar, Prisys Biotechnologies will discuss how PET, SPECT and MRI can be integrated with NHP research to support translational drug development. The speakers will introduce key imaging approaches and considerations, followed by selected case studies illustrating applications in CNS target engagement, biodistribution, therapeutic delivery and translational research.

Save Your Seat

What You Will Learn

How molecular imaging supports translational drug development
Key applications of PET, SPECT and MRI in NHP research

Approaches to assessing biodistribution and target engagement
How imaging can support longitudinal pharmacodynamic assessment
Integration of imaging with PK/PD and other translational endpoints
Practical NHP case studies in CNS research and therapeutic delivery

Key Topics

PET, SPECT and MRI: capabilities, applications and complementary roles
Radiotracer selection and considerations for quantitative molecular imaging
Target engagement and receptor occupancy, where appropriate

Longitudinal assessment of pharmacodynamic and biological responses
Molecular imaging applications in CNS research and NHP models
PET-based tracking of biologics, cells and other therapeutic modalities

Radio-isotope Imaging — Choices on Isotopes

Speakers

James Song

General Manager, PRISYS Biotech

As General Manager of Prisys Biotech, James Song leverages 20 years of experience in NHP pharmacology and disease modeling to accelerate the transition from lab to clinic. He is a specialist in navigating the complexities of translational medicine, with a proven track record in managing high-value asset restructuring and forging strategic international alliances. Under his leadership, Prisys has strengthened its global footprint through sophisticated laboratory infrastructure, unique NHP models, and integrated NHP breeding operations.

Message Presenter

Radioisotope manufacture & Labeling — Isotope selection for different compounds

Webinar Key Agenda

Why Molecular Imaging Matters in Translational Drug Development

The role of longitudinal imaging in generating quantitative and mechanistic evidence beyond conventional endpoint measurements.

Molecular Imaging Technologies: From Tracer Selection to Quantitative Readouts

PET, SPECT and MRI, including tracer selection, quantitative imaging and applications in drug development.

Case Studies: From Distribution to Target Engagement and Biological Response

Selected NHP case studies covering CNS target engagement, biodistribution and therapeutic delivery.

From Imaging Data to an Integrated NHP Translational Package

Integrating imaging with NHP models, PK/PD, biomarkers and behavioral or functional endpoints.

Learn more: Biodistribution Imaging Service

Join the Webinar

How PET, SPECT and MRI Can Provide Longitudinal Insights into Drug Distribution, Target Engagement and Biological Response

📅 September 10, 2026 EDT 21:00 / PDT 18:00

Register Now